SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24 2022 - 8:30AM
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the "Company" or
"SciSparc"), today announced positive safety profile results from
its joint pre-clinical trial with Clearmind Medicine Inc.
(“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0), a
psychedelic pharmaceutical company focused on the discovery and
development of novel psychedelic-derived therapeutics to solve
widespread and underserved health problems. The trial tested the
proprietary combination of SciSparc's CannAmide™ with Clearmind's
psychedelic molecule, MEAI, for alcohol consumption.
A histopathology assessment was conducted on several organs
(heart, lungs, liver, kidneys, brain, pancreas, spleen, and thyroid
gland) from all experiment groups (n=3-5 per group) to determine
the safety of the proprietary combination of MEAI and CannAmide™
versus control (mice) that were not exposed to alcohol). The
severity of changes was scored by a 5-point scale by a qualified
blinded toxicologist (Schafer et al., Toxicol Pathol 2018,
46:256-265). The results indicated a high safety profile of the
combination treatment with no treatment-related changes
observed.
Oz Adler, SciSparc's Chief Executive Officer,
commented, "We are pleased with these latest results that confirm
the high safety profile of the psychedelic combination treatment.
Previous testing results showed high efficacy potential in treating
alcoholism when using this combination. We plan on further
exploring the safety and efficacy of combining our technology with
Clearmind's novel molecule."
Previously announced successful results showed a significant
dose dependent effect for the MEAI treatment in reducing alcohol
consumption in treated animals, with additional significant effect
when combining CannAmide™ with the lower sub-effective MEAI
dose.
Results showed that alcohol consumption was significantly
reduced following treatment with MEAI at a dose of 40 mg/kg and
higher (p<0.01) compared to consumption before treatment.
Alcohol consumption was significantly reduced following dual
treatment with 25 mg/kg CannAmide™ in addition to MEAI at a dose of
20 mg/kg compared to consumption before treatment. The mice were
provided with 20% alcohol solution for 24 hours, three times a
week, for seven weeks, and were treated every day with MEAI or
MEAI/CannAmide™ during the last two weeks of alcohol treatment. The
alcohol consumption was measured by weighing the alcohol bottles
before and after; water consumption was measured similarly in
parallel.
About SciSparc (NASDAQ:
SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of
Tourette syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of autism spectrum disorder and status epilepticus.
About Clearmind Medicine
Clearmind Medicine is a new biotech company focused on the
discovery and development of novel psychedelic-derived therapeutics
to solve widespread and underserved health problems, including
alcohol use disorder, binge eating and depression.
The Israeli-Canadian company holds several patents for the
non-hallucinogenic compound MEAI. The company intends to seek
additional patents for its compounds whenever warranted and will
remain opportunistic regarding the acquisition of additional
intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian
Securities Exchange under the symbol "CMND", the Frankfurt Stock
Exchange under the symbol “CWYO” and on the OTC pink under the
symbol "CMNDF".
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses the potential benefits of MEAI
treatment and its potential in reducing alcohol consumption of the
treated animals, with additional significant effect for the
CannAmide™ treatment at the lower sub-effective MEAI dose, and its
plans to further explore the safety and efficacy of combining MEAI
and CannAmide™. Historic results of scientific research and
clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. Because such statements deal with future
events and are based on SciSparc's current expectations, they are
subject to various risks and uncertainties and actual results,
performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
including those discussed under the heading "Risk Factors" in
SciSparc's Annual Report on Form 20-F filed with the SEC
on April 28, 2022 , and in subsequent filings with the
U.S. Securities and Exchange Commission. Except as otherwise
required by law, SciSparc disclaims any intention or obligation to
update or revise any forward-looking statements, which speak only
as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Investor Contact:IR@scisparc.comTel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024